The oral GLP-1 pill race added another contender this week: on July 7, 2026, Kailera Therapeutics and Hengrui Pharma reported positive Phase 3 topline data for KAI-7535 (Hengrui's HRS-7535), a once-daily oral small-molecule GLP-1 that drove up to 11% weight loss. It's a real Phase 3 readout — but it comes from trials run in China, which leaves the only question that matters for most US readers: what can you actually get today?
Research-context information only. This article reports trial data and what it means for buyers. Retatrutide is an investigational drug not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. It is not medical advice. Talk to a licensed physician before starting any GLP-1 protocol.
The short version: KAI-7535 is promising and entirely unavailable in the US. The oral and injectable routes that exist right now are FDA-approved orforglipron and compounded GLP-1 peptides — and that gap is exactly what most "new GLP-1 pill" searches miss.
What Kailera and Hengrui Showed
KAI-7535 is a once-daily oral small-molecule GLP-1 receptor agonist. That "small molecule" distinction matters: unlike injectable peptides such as semaglutide or tirzepatide, it survives the gut and works as a pill, the same convenience profile as orforglipron. The July 7 announcement covered two separate Phase 3 trials Hengrui ran in China.
HARBOR-1 (obesity) enrolled 556 adults with obesity (mean BMI 34.0). Over 44 weeks:
| Dose | Weight loss (44 wks) | Week 50 |
|---|---|---|
| KAI-7535 180 mg | ~10.9% | ~11.1% |
| KAI-7535 120 mg | ~9.5% | ~9.5% |
| Placebo | ~2.5% | — |
At the 180 mg dose, 68% of participants lost at least 5% of body weight, 47% lost at least 10%, and 26% lost at least 15%. The dominant side effects were the usual GLP-1 GI complaints — nausea, vomiting, and diarrhea — but treatment discontinuation stayed low at about 3.1% on the top dose, only slightly above placebo (2.7%).
OUTSTAND-2 (type 2 diabetes) enrolled 810 adults with a mean starting HbA1c of 8.6%. KAI-7535 cut HbA1c by up to 1.68% at week 32, beating the dapagliflozin comparator (1.28%), with no Grade 3 hypoglycemic events and no liver safety signals.
The catch on timing: these are Hengrui's China trials. Kailera's own global Phase 2 program for KAI-7535 only started in April 2026, enrolling roughly 320 participants with doses escalating to 360 mg, and topline data isn't expected until 2027. So a US filing is realistically years out.
What This Means for You
Here is the part the press release buries: there is no way to buy KAI-7535. The Phase 3 data is real, but it's a Chinese regulatory readout for a proprietary small molecule — not a peptide that compounding pharmacies or research vendors can synthesize. Kailera's US program is still mid-Phase 2. Anyone selling "KAI-7535" or "HRS-7535" today is selling something else.
So if the headlines sent you looking for an oral GLP-1, you have exactly two legitimate routes right now.
Route 1: The oral pill that already exists — orforglipron
Orforglipron (Foundayo) was FDA-approved in April 2026 — the first oral GLP-1 with no food or water restrictions, the same class KAI-7535 is chasing. It delivered roughly 12-13% weight loss in Phase 3 and runs about $149/month self-pay, with commercial-insurance copays as low as $25 and Medicare Part D access that started July 1, 2026. It's a prescription drug, available through retail pharmacies and telehealth today. If a daily pill is the goal, orforglipron is the only approved one on the US market.
Route 2: Compounded injectable GLP-1 peptides
For readers prioritizing weight-loss magnitude over pill convenience, compounded GLP-1 peptides remain the access route most of our readers report using. This week's news doesn't change that landscape — vetted vendors with current COA documentation still carry the three workhorses:
- Best Semaglutide Vendors — current pricing on 5mg and 10mg vials
- Best Tirzepatide Vendors — pricing on 10mg, 30mg, and 60mg vials
- Best Retatrutide Vendors — the triple agonist with the highest Phase 3 weight-loss numbers to date
- All Active Vendor Coupons — current discount codes across recommended vendors
The honest framing: KAI-7535 may eventually be a cheaper oral option than today's route — a pill, no needles, no reconstitution, and a small-molecule manufacturing base that could undercut branded pricing. But "eventually" is years out, and it's China-first. The decision in front of you now is orforglipron versus an injectable peptide, not KAI-7535 versus anything.
